Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 12:4:32.
doi: 10.1186/s40608-017-0168-y. eCollection 2017.

Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery

Affiliations

Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery

Brian M Parker et al. BMC Obes. .

Abstract

Background: Roux-en-Y gastric bypass (RYGB) improves the pathophysiology that contributes to obesity-related nonalcoholic steatohepatitis (NASH). Whether obesity-related fibrosis improves is unclear. We hypothesized that RYGB reverses NASH and fibrosis, and indocyanine green (ICG) clearance provides a sensitive measure for detecting asymptomatic fatty liver disease.

Methods: One hundred six obese adults scheduled for RYGB had preoperative liver function assessed using standard tests and ICG clearance and core liver biopsies obtained during RYGB. Once patients lost 60% of their preoperative weight or weight loss plateaued, liver function was reassessed. Repeat liver biopsies were obtained on patients with NASH at the time of RYGB.

Results: RYGB improved steatosis, lobular inflammation, hepatocyte ballooning and fibrosis. Serum albumin, AST, and ALT decreased the most in patients with NASH and NASH plus fibrosis. Twenty seven (26%) patients had normal baseline liver histology and 45 (43%) had NASH or NASH plus fibrosis. Nine of 13 patients with substantial fatty liver had normalized histology after weight loss, while severity of disease in the rest had stabilized or was reduced. Mean ICG clearance in patients with normal/mild fatty liver disease and those with histological fatty livers did not differ significantly.

Conclusions: RYGB surgery reverses NASH and liver fibrosis. Underlying mechanisms that facilitate improvement remain unclear.

Keywords: Anesthesia; Fatty; Fibrosis; Liver; Non-alcoholic steatohepatitis; Roux-en-Y gastric bypass.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by Institutional Review Board of Cleveland Clinic. All participants provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Receiver operating characteristic curves with area under the curve and standard error in parentheses. Displayed are the biochemical liver function tests and non- invasive ICG clearance test at pre-RYGB predicting significant fatty liver disease (nonalcoholic steatohepatitis). ICG = indocyanine green, RYGB = Roux-en-Y gastric bypass
Fig. 2
Fig. 2
Receiver operating characteristic curves with area under the curve and standard error n parentheses for a multivariable model using all the preoperative liver function tests (except PTT due to a large proportion of missing values) and the ICG k value at pre-RYGB to predict significant fatty liver disease. Significant fatty liver, including nonalcoholic steatohepatitis (NASH) and NASH plus fibrosis, is defined as steatosis >5% with at least a few balloon cells and lobular inflammation >2 foci/200×. ICG = indocyanine green, PTT = Partial Thromboplastin Time, RYGB = Roux-en-Y gastric bypass

References

    1. Ogden CL, Carroll MD, Flegal KM. Prevalence of obesity in the United States. JAMA. 2014;312:189–190. doi: 10.1001/jama.2014.6228. - DOI - PubMed
    1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112. doi: 10.1002/hep.20973. - DOI - PubMed
    1. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi: 10.1002/hep.20701. - DOI - PubMed
    1. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007;86:285–300. - PubMed
    1. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg. 2006;16:1278–1286. doi: 10.1381/096089206778663805. - DOI - PubMed

LinkOut - more resources